Shots: Novo has acquired Ziylo to develop glucose responsive insulins, leading to a better metabolic control and reducing diabetic rates Novo has paid an upfront payment to Ziylo ~$800 mn and earn-outs with possibility of milestone payments In an ongoing deal, Novo has a research collaboration with Carbometrics, to develop glucose responsive insulins Click here […]Read More
